TransMedics (TMDX) director Merilee Raines receives 2,922 RSU award

Rhea-AI Filing Summary

RAINES MERILEE reported acquisition or exercise transactions in this Form 4 filing.

TransMedics Group director Merilee Raines received an equity grant of 2,922 restricted stock units (RSUs) on common stock. These RSUs are a form of stock-based compensation, with each unit representing the right to receive one TransMedics common share. Following this award, Raines directly holds 6,981 common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider RAINES MERILEE

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,922	$0.00	--

Holdings After Transaction: Common Stock — 6,981 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 2,922 units Shares after transaction: 6,981 shares Transaction price: $0.00 per share +2 more

5 metrics

RSU grant size 2,922 units Restricted stock units awarded on common stock

Shares after transaction 6,981 shares Direct common stock holdings after RSU award

Transaction price $0.00 per share Form 4 shows zero cash price for RSU grant

Transaction code A Grant, award, or other acquisition of common stock

Transaction direction acquire Transaction classified as grant/award acquisition

Key Terms

restricted stock units ("RSUs"), contingent right, Form 4, transaction code "A"

4 terms

restricted stock units ("RSUs") financial

"Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

transaction code "A" regulatory

"transaction_code": "A""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RAINES MERILEE

(Last) (First) (Middle)

C/O TRANSMEDICS GROUP, INC.

200 MINUTEMAN ROAD

(Street)

ANDOVER MASSACHUSETTS 01810

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TransMedics Group, Inc. [ TMDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/20/2026		A		2,922(1)	A	$0	6,981	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

	By: /s/ Gerardo Hernandez, Attorney-in-Fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did TransMedics (TMDX) director Merilee Raines report in this Form 4?

Merilee Raines reported receiving an award of 2,922 restricted stock units in TransMedics common stock. The Form 4 shows this as a grant-type acquisition with no cash price per share, increasing her directly held position to 6,981 common shares after the award.

How many TransMedics (TMDX) shares does Merilee Raines hold after this transaction?

After the reported grant, Merilee Raines directly holds 6,981 shares of TransMedics common stock. This total includes the newly awarded 2,922 restricted stock units, each of which represents a contingent right to receive one share of TransMedics common stock in the future.

What type of transaction is reported for TransMedics (TMDX) director Merilee Raines?

The transaction is a grant or award acquisition coded “A” on the Form 4. It represents 2,922 restricted stock units, a form of stock-based compensation, rather than an open-market purchase or sale. The transaction price per share is shown as zero dollars.

What are the 2,922 RSUs reported by Merilee Raines at TransMedics (TMDX)?

The 2,922 RSUs are restricted stock units, each representing a contingent right to receive one TransMedics common share. They are part of an equity compensation grant, not immediately tradable shares, and typically settle into common stock when vesting conditions are satisfied.

Does this TransMedics (TMDX) Form 4 show any stock sales by Merilee Raines?

No stock sales are reported; the Form 4 only shows an acquisition via a grant of 2,922 restricted stock units. The summary data lists one acquisition transaction, no sales, and reflects an increase in Merilee Raines’ directly held common stock position to 6,981 shares.